Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 31, 2019 10:15 ET | Source: Motif Bio plc

Result of Annual General Meeting

NEW YORK, May 31, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Annual...
May 22, 2019 08:50 ET | Source: Motif Bio plc

Motif Bio plc AGM Statement

NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Company’s...
May 22, 2019 02:00 ET | Source: Motif Bio plc

Motif Bio to Evaluate Orphan Disease Opportunity for Iclaprim in Ophthalmology

NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company...
May 21, 2019 02:00 ET | Source: Motif Bio plc

Motif Bio to Present Iclaprim Data at ASM Microbe 2019

NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that three...
May 03, 2019 13:25 ET | Source: Motif Bio plc

Motif Bio meeting with U.S. FDA held as planned

NEW YORK, May 03, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, confirms that the Company met...
May 01, 2019 02:00 ET | Source: Motif Bio plc

Motif Bio Signs Agreement with Lamellar Biomedical

NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company...
April 26, 2019 02:01 ET | Source: Motif Bio plc

Motif Bio plc: Notice of Annual General Meeting

NEW YORK, April 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc ("Motif Bio" or the "Company") (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics,...
April 26, 2019 02:00 ET | Source: Motif Bio plc

Motif Bio Announces Appointment of Andrew Powell to Board of Directors

NEW YORK, April 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics,...
April 16, 2019 02:00 ET | Source: Motif Bio plc

Motif Bio Presents New Iclaprim Data at ECCMID 2019

NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that new...
April 15, 2019 02:00 ET | Source: Motif Bio plc

Motif Bio Reports Fiscal Year 2018 Results

NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial...